Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rho GDP dissociation inhibitor beta (ARHGDIB)
- Target
- ARHGDIB
- Molecular classification
- Regulatory protein, Small GTPase regulator, GDP dissociation inhibitor, Other
01
Overview
Rho GDP dissociation inhibitor beta (ARHGDIB) is a regulatory protein that inhibits the dissociation of GDP from Rho family GTPases, thereby controlling their activation and regulating the actin cytoskeleton, cell signaling, and cell proliferation. It is implicated in various signaling pathways and diseases, notably in certain cancers and metabolic disorders. ARHGDIB is a member of the Rho GDIs, which finely regulate the active/inactive state of small GTPases involved in cytoskeletal dynamics and cell movement[1][5][6].
- Other names
- Rho GDP-dissociation inhibitor 2GDIA2GDID4RAP1GN1Rho GDI 2Ly-GDIRhoGDI2rho-GDI betaD4LYGDI
02
Mechanism of action
Inhibition of GDP dissociation from Rho GTPases and modulation of Rho protein-mediated signaling pathways.
03
Biological functions
Regulation of GDP/GTP exchange on Rho GTPasesRegulation of actin cytoskeletonSignal transductionCell proliferationApoptosis and survival signaling
04
Disease associations
CancerHyperinsulinemic hypoglycemiaGastric cancerOther
05
Safety considerations
Functional redundancy with other GDIs may limit therapeutic specificityPotential effects on multiple cell signaling pathways could lead to off-target effects
06
Biomarkers
Associated with gastric cancer prognosisExpression level may be a biomarker for cancer and metabolic disease (context-dependent)
Beyond the preview
Go deeper on Rho GDP dissociation inhibitor beta (ARHGDIB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rho GDP dissociation inhibitor beta (ARHGDIB).